Kaitlin Nicholson

CLIN AST PROF

MD-OBSTETRICS - GYNECOLOGY

sort by:

GRANT
A Phase III Trial of One vs. Two Years of Maintenance Olaparib, With or Without Bevacizumab, in Patients With BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy
National Institute of Health Nci16 Jan 2025 - 28 Feb 2029
Active

GRANTS